JPMorgan Upgrades Integra LifeSciences (IART) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Integra LifeSciences (IART) Tops Q2 EPS by 3c; Updates FY15 Outlook
July 30, 2015 8:51 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.79, $0.03 better than the analyst estimate of $0.76. Revenue for the quarter came in at $0 versus the consensus estimate of $239.91 million.
Integra LifeSciences sees FY2015 EPS of $3.00-$3.10, versus the consensus of $3.11. Integra LifeSciences sees FY2015 revenue of... More
